Skip to content
Screener

Alumis Inc. ALMS Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.9×-0.9×
Amgen logo
AmgenAMGN
4.9×-2.7×
Immunome logo
ImmunomeIMNM
0.0×
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
0.0×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0.0×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
0.5×-0.2×

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s debt-to-equity?
Alumis Inc. (ALMS) reported debt-to-equity of 0.1× in Q1 2026.
How has Alumis Inc.'s debt-to-equity changed year-over-year?
Alumis Inc.'s debt-to-equity increased by 487.9% year-over-year, from 0× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Alumis Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude